Colon and Rectosigmoid Junction – V9: 2027+
| Primary Site | Histology | Year of Diagnosis |
|---|---|---|
| C180, C182-C189, C199 | 8000-8149, 8154, 8160-8231, 8243-8248, 8250-8682, 8690-8700, 8720-8790, 8940-8960, 8965-8983, 9000, 9050-9111, 9270, 9300-9312, 9340-9363, 9380-9539, 9541 | 2027-9998, 9999, <BLANK> |
Notes
**See table above for primary sites and histologies for this schema** C180: Cecum C182: Ascending colon C183: Hepatic flexure of colon C184: Transverse colon C185: Splenic flexure of colon C186: Descending colon C187: Sigmoid colon C188: Overlapping lesion of colon C189: Colon, NOS C199: Rectosigmoid junction **Note 1:** **Sources used in the development of this schema** * SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf) * SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/) * Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx * Chapter 20 *Colon and Rectum*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois. * *Colon and Rectum*, from the AJCC Cancer Staging System Version 9 (2027). Used with permission of the American College of Surgeons, Chicago, Illinois. Colon, from the AJCC Cancer Staging System Version 9 (2026). Used with permission of the American College of Surgeons, Chicago, Illinois. **Note 2:** **Other EOD Schemas with Colon sites** * **Appendix**: 8000-8149, 8154, 8160-8231, 8243-8248, 8250-8682, 8690-8700, 8720-8790 * **GIST**: 8935-8936 * **Kaposi Sarcoma**: 9140 * **Mycosis Fungoides**: 9700-9701 * **NET Appendix**: 8150-8153, 8155-8156, 8158, 8240-8242, 8249, 8683 * **NET Colon and Rectum**: 8150-8153, 8155-8156, 8158, 8240-8242, 8249, 8683 * **Soft Tissue Abdomen and Thoracic**: 8710-8714, 8800-8803, 8810-8921, 8932-8934, 8963-8964, 8990, 8992, 9010-9016, 9030-9043, 9045, 9120-9138, 9141-9230, 9240-9262, 9271-9290, 9320-9330, 9364-9373, 9540, 9542-9580, 9582 * **Soft Tissue Rare**: 8804-8806, 8930-8931, 8991, 9020, 9044, 9231, 9581Data Items
| Name | Default Value | Used in Derivation | NAACCR Item | Required By | Metadata |
|---|---|---|---|---|---|
| Year of Diagnosis | Yes |
NAACCR #390
dateOfDiagnosis |
None | ||
| Primary Site | Yes |
NAACCR #400
primarySite |
None | ||
| Histology | Yes |
NAACCR #522
histologicTypeIcdO3 |
None | ||
| Behavior | No |
NAACCR #523
behaviorCodeIcdO3 |
None | ||
| Type of Reporting Source | No |
NAACCR #500
typeOfReportingSource |
None | ||
| Tumor Size Clinical | No |
NAACCR #752
tumorSizeClinical |
None | ||
| Tumor Size Pathological | No |
NAACCR #754
tumorSizePathologic |
None | ||
| Tumor Size Summary | 999 | No |
NAACCR #756
tumorSizeSummary |
None | |
| Regional Nodes Positive | 99 | No |
NAACCR #820
regionalNodesPositive |
None | |
| Regional Nodes Examined | 99 | No |
NAACCR #830
regionalNodesExamined |
None | |
| EOD Primary Tumor | 999 | Yes |
NAACCR #772
eodPrimaryTumor |
None | |
| EOD Regional Nodes | 999 | Yes |
NAACCR #774
eodRegionalNodes |
None | |
| EOD Mets | 00 | Yes |
NAACCR #776
eodMets |
None | |
| SS2018 | No |
NAACCR #764
summaryStage2018 |
None | ||
| Grade Clinical | 9 | Yes |
NAACCR #3843
gradeClinical |
All | SSDI |
| Grade Pathological | 9 | Yes |
NAACCR #3844
gradePathological |
All | SSDI |
| Grade Post Therapy Clin (yc) | No |
NAACCR #1068
gradePostTherapyClin |
COC NPCR SEER |
SSDI | |
| Grade Post Therapy Path (yp) | No |
NAACCR #3845
gradePostTherapy |
CCCR/Canada COC NPCR SEER |
SSDI | |
| CEA PreTX Lab Value | XXXX.8 | No |
NAACCR #3820
ceaPretreatmentLabValue |
COC SEER |
SSDI |
| CEA PreTX Interpretation | 8 | No |
NAACCR #3819
ceaPretreatmentInterpretation |
CCCR/Canada COC SEER |
SSDI |
| Tumor Deposits | X8 | No |
NAACCR #3934
tumorDeposits |
COC SEER 2018–2023 SEER (RC) 2024– |
SSDI |
| Perineural Invasion | 8 | No |
NAACCR #3909
perineuralInvasion |
COC SEER |
SSDI |
| Circumferential Resection Margin | XX.8 | No |
NAACCR #3823
circumferentialResectionMargin |
CCCR/Canada COC SEER |
SSDI |
| KRAS | 8 | No |
NAACCR #3866
kras |
COC SEER |
SSDI |
| Microsatellite Instability (MSI) | 8 | No |
NAACCR #3890
microsatelliteInstability |
CCCR/Canada COC NPCR SEER |
SSDI |
| BRAF Mutational Analysis | 8 | No |
NAACCR #3940
brafMutationalAnalysis |
COC 2021– SEER 2021– |
SSDI 2021– |
| NRAS Mutational Analysis | 8 | No |
NAACCR #3941
nrasMutationalAnalysis |
COC 2021– SEER 2021– |
SSDI 2021– |
| Neoadjuvant Therapy | 9 | No |
NAACCR #1632
neoadjuvantTherapy |
SEER 2021– | SSDI 2021– |
| Neoadjuvant Therapy – Clinical Response | 99 | No |
NAACCR #1633
neoadjuvTherapyClinicalResponse |
SEER 2021– | SSDI 2021– |
| Neoadjuvant Therapy – Treatment Effect | 9 | No |
NAACCR #1634
neoadjuvTherapyTreatmentEffect |
COC 2027– SEER 2021– |
SSDI 2021– |
Initial Context
Outputs
| Name | Default Value | Description | NAACCR Item | Metadata |
|---|---|---|---|---|
| Schema ID | 09201 |
NAACCR #3800
schemaId |
None | |
| Derived Version | {{ctx_alg_version}} | None | None | |
| Derived Summary Stage 2018 | 9 |
NAACCR #762
derivedSummaryStage2018 |
None | |
| Derived Summary Grade 2018 | <BLANK> |
NAACCR #1975
derivedSummaryGrade2018 |
None |